A new trading day began on Friday, with Halozyme Therapeutics Inc (NASDAQ: HALO) stock price down -15.40% from the previous day of trading, before settling in for the closing price of $53.96. HALO’s price has ranged from $33.15 to $65.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 41.16%. Meanwhile, its annual earnings per share averaged 43.80%. With a float of $125.86 million, this company’s outstanding shares have now reached $126.77 million.
Let’s determine the extent of company efficiency that accounts for 373 employees. In terms of profitability, gross margin is 78.34%, operating margin of 50.35%, and the pretax margin is 50.68%.
Halozyme Therapeutics Inc (HALO) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Halozyme Therapeutics Inc is 1.09%, while institutional ownership is 99.34%. The most recent insider transaction that took place on Oct 15 ’24, was worth 537,469. In this transaction SVP, CHIEF TECHNICAL OFFICER of this company sold 10,000 shares at a rate of $53.75, taking the stock ownership to the 173,756 shares. Before that another transaction happened on Oct 16 ’24, when Company’s SVP, CHIEF TECHNICAL OFFICER sold 10,000 for $53.26, making the entire transaction worth $532,590. This insider now owns 173,756 shares in total.
Halozyme Therapeutics Inc (HALO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 43.80% per share during the next fiscal year.
Halozyme Therapeutics Inc (NASDAQ: HALO) Trading Performance Indicators
Here are Halozyme Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.19. Likewise, its price to free cash flow for the trailing twelve months is 12.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.02, a number that is poised to hit 1.17 in the next quarter and is forecasted to reach 4.60 in one year’s time.
Technical Analysis of Halozyme Therapeutics Inc (HALO)
Looking closely at Halozyme Therapeutics Inc (NASDAQ: HALO), its last 5-days average volume was 2.85 million, which is a jump from its year-to-date volume of 1.32 million. As of the previous 9 days, the stock’s Stochastic %D was 21.61%. Additionally, its Average True Range was 2.80.
During the past 100 days, Halozyme Therapeutics Inc’s (HALO) raw stochastic average was set at 0.13%, which indicates a significant decrease from 0.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 96.89% in the past 14 days, which was higher than the 49.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $56.04, while its 200-day Moving Average is $49.02. However, in the short run, Halozyme Therapeutics Inc’s stock first resistance to watch stands at $48.32. Second resistance stands at $50.99. The third major resistance level sits at $52.33. If the price goes on to break the first support level at $44.30, it is likely to go to the next support level at $42.96. Now, if the price goes above the second support level, the third support stands at $40.29.
Halozyme Therapeutics Inc (NASDAQ: HALO) Key Stats
With a market capitalization of 4.91 billion, the company has a total of 127,227K Shares Outstanding. Currently, annual sales are 829,250 K while annual income is 281,590 K. The company’s previous quarter sales were 290,080 K while its latest quarter income was 137,010 K.
